Claudin-18.2 and gastric cancer: from physiology to carcinogenesis

Bunga O.D.; Danilova N.V.

doi:https://doi.org/10.17116/patol20248606192

Рекомендуем статьи по данной теме:

Клинический случай успешного лечения рака желудка IV стадии. Онкология. Журнал им. П.А. Герцена. 2024;(5):54-58

Ингибиторы иммунных контрольных точек в качестве компонента периоперационной терапии у пациентов с резектабельным раком пищевода и кардиоэзофагеального перехода. Онкология. Журнал им. П.А. Герцена. 2024;(5):62-68

Локальный цитокиновый профиль эндометрия у пациенток с повторными неудачами имплантации и его фармакологическая коррекция секретомом мононуклеаров периферической крови. Проблемы репродукции. 2024;(5):46-54

Панкреатодуоденальная резекция в составе мультивисцеральных операций. Хирургия. Журнал им. Н.И. Пирогова. 2024;(11):77-83

Эффективность альфа-глутамил-триптофана в лечении хронического атрофического гастрита на клинических примерах. Доказательная гастроэнтерология. 2024;(4):121-128

Опыт успешного лечения несостоятельности высоких пищеводно-кишечных анастомозов после гастрэктомии посредством видеоторакоскопической санации и циклов вакуумной активной системы аспирации. Онкология. Журнал им. П.А. Герцена. 2024;(6):63-69

Антигенные рецепторы в разработке CAR-T клеток для иммунотерапии глиобластомы. Онкология. Журнал им. П.А. Герцена. 2024;(6):91-95

Рак желудка: заболеваемость, факторы риска, скрининг. Профилактическая медицина. 2024;(12):135-139

Возможности применения бактериальных лизатов в лечении и профилактике инфекционных заболеваний верхних дыхательных путей. Российская ринология. 2024;(4):314-322

Резюме / Abstract:

На сегодняшний день глобальную проблему для человечества представляют онкологические заболевания, в частности рак желудка, который характеризуется высокой смертностью и агрессивностью течения. В связи с этим происходит поиск новых подходов к диагностике и терапии рака желудка, одним из таких направлений является исследование уровня экспрессии молекулы межклеточной адгезии клаудина-18.2 в опухолевой ткани и использование его в качестве молекулы-мишени. В случае разных патологических процессов, в том числе опухолевых, профиль экспрессии клаудина-18.2 изменяется, что свидетельствует о его возможной роли в инициации и прогрессировании рака. Цель данного обзора — систематизация данных о клаудине-18.2, его роли в нормальной физиологии клетки и эмбриологии, а также в развитии патологических процессов в желудке, о связи с клинико-морфологическими характеристиками рака желудка и значении в биологической терапии.

Ключевые слова / Keywords:

клаудин-18.2

рак желудка

гастрит

иммунотерапия

Авторы / Authors:

Бунга О.Д.

Медицинский научно-образовательный институт МГУ имени М.В. Ломоносова

ORCID: 0009-0009-9345-0353

Данилова Н.В.

Медицинский научно-образовательный институт МГУ имени М.В. Ломоносова

SPIN РИНЦ: 6878-2025
Scopus AuthorID: 36613033400
ResearcherID: H-6477-2014
ORCID: 0000-0001-7848-6707

Дата поступления:

08.05.2024

Дата принятия в печать:

26.06.2024

Закрыть метаданные

Литература / References:

Tsukita S, Tanaka H, Tamura A. The claudins: from tight iunctions to biological systems. Trends Biochem Sci. 2019;44(2):141-152. https://doi.org/10.1016/J.TIBS.2018.09.008
Türeci Ö, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481(2):83-92. https://doi.org/10.1016/J.GENE.2011.04.007
Baumholtz AI, Gupta IR, Ryan AK. Claudins in morphogenesis: forming an epithelial tube. Tissue Barriers. 2017;5(4):e1361899. https://doi.org/10.1080/21688370.2017.1361899
Zuo JY, Tong YJ, Yue DM. [A review on the effect of Claudin-18 on bronchopulmonary dysplasia in preterm infants]. Zhongguo Dang Dai Er Ke Za Zhi 2021;23(5):542-547. (In Chinese). https://doi.org/10.7499/J.ISSN.1008-8830.2101025
Zhou B, Flodby P, Luo J, Castillo DR, Liu Y, Yu FX, McConnell A, Varghese B, Li G, Chimge NO, et al. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J Clin Invest. 2018;128(3):970-984. https://doi.org/10.1172/JCI90429
Oshima T, Shan J, Okugawa T, Chen X, Hori K, Tomita T, Fukui H, Watari J, Miwa H. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS One. 2013;8(9):e74757. https://doi.org/10.1371/journal.pone.0074757
Nakayama I, Shinozaki E, Sakata S, Yamamoto N, Fujisaki J, Muramatsu Y, Hirota T, Takeuchi K, Takahashi S, Yamaguchi K, et al. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults. Cancer Sci. 2019;110(4):1352-1363. https://doi.org/10.1111/cas.13967
Yao F, Kausalya JP, Sia YY, Teo AS, Lee WH, Ong AG, Zhang Z, Tan JH, Li G, Bertrand D, et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep. 2015;12(2):272-285. https://doi.org/10.1016/j.celrep.2015.06.020
Zhang WH, Zhang SY, Hou QQ, Qin Y, Chen XZ, Zhou ZG, Shu Y, Xu H, Hu JK. The significance of the CLDN18-ARHGAP fusion gene in gastric cancer: a systematic review and meta-analysis. Front Oncol. 2020;10:1214. https://doi.org/10.3389/fonc.2020.01214
Li J. Context-dependent roles of claudins in tumorigenesis. Front Oncol. 2021;11:676781. https://doi.org/10.3389/FONC.2021.676781
Hagen SJ, Ang LH, Zheng Y, Karahan SN, Wu J, Wang YE, Caron TJ, Gad AP, Muthupalani S, Fox JG. Loss of tight junction protein claudin 18 promotes progressive neoplasia development in mouse stomach. Gastroenterology. 2018;155(6):1852-1867. https://doi.org/10.1053/J.GASTRO.2018.08.041
Tao D, Guan B, Li Z, Jiao M, Zhou C, Li H. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. Pathol Res Pract. 2023;248:154699. https://doi.org/10.1016/j.prp.2023.154699
Günzel D, Fromm M. Claudins and other tight junction proteins. Compr Physiol. 2012;2(3):1819-1852. https://doi.org/10.1002/CPHY.C110045
Sweerus K, Lachowicz-Scroggins M, Gordon E, LaFemina M, Huang X, Parikh M, Kanegai C, Fahy JV, Frank JA. Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma. J Allergy Clin Immunol. 2017;139(1):72-81.e1. https://doi.org/10.1016/J.JACI.2016.02.035
Hayashi D, Tamura A, Tanaka H, Yamazaki Y, Watanabe S, Suzuki K, Suzuki K, Sentani K, Yasui W, Rakugi H, et al. Deficiency of claudin-18 causes paracellular H+ leakage, up-regulation of interleukin-1β, and atrophic gastritis in mice. Gastroenterology. 2012;142(2):292-304. https://doi.org/10.1053/j.gastro.2011.10.040
Dottermusch M, Krüger S, Behrens HM, Halske C, Röcken C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch. 2019;475(5):563-571. https://doi.org/10.1007/s00428-019-02624-7
Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8(1):100762. https://doi.org/10.1016/J.ESMOOP.2022.100762
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, et al.; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-209. https://doi.org/10.1038/NATURE13480
Wang C, Wang Y, Chen J, Wang Y, Pang C, Liang C, Yuan L, Ma Y. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 2023;23(1):283. https://doi.org/10.1186/s12876-023-02924-y
Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, Yu J. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38. https://doi.org/10.1186/S40364-022-00385-1
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30(9):1487-1495. https://doi.org/10.1093/annonc/mdz199
Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10(1):105. https://doi.org/10.1186/s13045-017-0473-4
Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Türeci Ö. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol. 2019;49(9):870-876. https://doi.org/10.1093/JJCO/HYZ068
Liu S, Wong HY, Xie L, Kim Y, Shu D, Zheng B, Liu N, Xing C, Chen X, Dong Q. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis. Sci Rep. 2022;12(1):22024. https://doi.org/10.1038/s41598-022-24426-9
Liang Z, Liu L, Li W, Lai H, Li L, Wu J, Zhang H, Fang C. Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2023;13:1258347. https://doi.org/10.3389/FONC.2023.1258347
Shen L, Liu D, Li N, Guo W, Liu T, Li H, Li J, Bai Y, Deng Y, Zhuang Z, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002). J Clin Oncol. 2023;41(16_suppl):4046. https://doi.org/10.1200/JCO.2023.41.16_SUPPL.4046
Lordick F, Chao J, Buxò E, van Laarhoven HWM, Lima CMR, Lorenzen S, Dayyani F, Heinemann V, Greil R, Stienen S, et al. 1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. Ann Oncol. 2020;31:S928-S929. https://doi.org/10.1016/j.annonc.2020.08.2002
Yk W, Gong J, Sun Y, Zhang J, Ni S, Hou J, Chen X, Wang Y, Yu Q, Qu X, et al. Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. J Clin Oncol. 2023;41(4_suppl):382. https://doi.org/10.1200/JCO.2023.41.4_SUPPL.382
Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, Zhang H, Shi B, Jia J, Li Q, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409-418. https://doi.org/10.1093/jnci/djy134
Entezam M, Sanaei MJ, Mirzaei Y, Mer AH, Abdollahpour-Alitappeh M, Azadegan-Dehkordi F, Bagheri N. Current progress and challenges of immunotherapy in gastric cancer: a focus on CAR-T cells therapeutic approach. Life Sci. 2023;318:121459. https://doi.org/10.1016/j.lfs.2023.121459
Krause G, Protze J, Piontek J. Assembly and function of claudins: structure-function relationships based on homology models and crystal structures. Semin Cell Dev Biol. 2015;42:3-12. https://doi.org/10.1016/J.SEMCDB.2015.04.010
Günzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93(2):525-569. https://doi.org/10.1152/PHYSREV.00019.2012
Elkouby-Naor L, Ben-Yosef T. Functions of claudin tight junction proteins and their complex interactions in various physiological systems. Int Rev Cell Mol Biol. 2010;279(C):1-32. https://doi.org/10.1016/S1937-6448(10)79001-8
Hagen SJ. Non-canonical functions of claudin proteins: beyond the regulation of cell-cell adhesions. Tissue Barriers. 2017;5(2): e1327839. https://doi.org/10.1080/21688370.2017.1327839
Данилова Н.В., Аникина К.А., Олейникова Н.А., Вычужанин Д.В., Мальков П.Г. Экспрессия клаудина-3 в раке желудка. Архив патологии. 2020;82(2):5-11. https://doi.org/10.17116/PATOL2020820215
Yano K, Imaeda T, Niimi T. Transcriptional activation of the human claudin-18 gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G336-G343. https://doi.org/10.1152/ajpgi.00328.2007
Linares GR, Brommage R, Powell DR, Xing W, Chen ST, Alshbool FZ, Lau KH, Wergedal JE, Mohan S. Claudin 18 is a novel negative regulator of bone resorption and osteoclast differentiation. J Bone Miner Res. 2012;27(7):1553-1565. https://doi.org/10.1002/JBMR.1600
Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, Kimura S. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol. 2001;21(21):7380-7390. https://doi.org/10.1128/MCB.21.21.7380-7390.2001
LaFemina MJ, Sutherland KM, Bentley T, Gonzales LW, Allen L, Chapin CJ, Rokkam D, Sweerus KA, Dobbs LG, Ballard PL, et al. Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice. Am J Respir Cell Mol Biol. 2014;51(4):550-558. https://doi.org/10.1165/RCMB.2013-0456OC
Zou J, Li Y, Yu J, Dong L, Husain AN, Shen L, Weber CR. Idiopathic pulmonary fibrosis is associated with tight junction protein alterations. Biochim Biophys Acta Biomembr. 2020;1862(5):183205. https://doi.org/10.1016/J.BBAMEM.2020.183205
Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208(5):633-642. https://doi.org/10.1002/path.1922
Tabariès S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2017;36(9):1176-1190. https://doi.org/10.1038/onc.2016.289
Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Rau B, Stein U, Treese C. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22(12): 2357-2363. https://doi.org/10.1007/S12094-020-02380-0
Kim HD, Choi E, Shin J, Lee IS, Ko CS, Ryu MH, Park YS. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer. Sci Rep. 2023;13(1):20047. https://doi.org/10.1038/s41598-023-47178-6
Baek JH, Park DJ, Kim GY, Cheon J, Kang BW, Cha HJ, Kim JG. Clinical implications of claudin18.2 expression in patients with gastric cancer. Anticancer Res. 2019;39(12):6973-6979. https://doi.org/10.21873/anticanres.13919
Kim SR, Shin K, Park JM, Lee HH, Song KY, Lee SH, Kim B, Kim SY, Seo J, Kim JO, et al. Clinical significance of CLDN18.2 expression in metastatic diffuse-type gastric cancer. J Gastric Cancer. 2020;20(4):408-420. https://doi.org/10.5230/jgc.2020.20.e33
Xu H, Li W, Lv H, Gu D, Wei X, Dai H. Tandem CAR-T cells targeting CLDN18.2 and NKG2DL for treatment of gastric cancer. J Clin Oncol. 2022;40(16_suppl):4030. https://doi.org/10.1200/JCO.2022.40.16_SUPPL.4030